A major stage in biotherapeutic development is to understand the immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of the drug candidate to evaluate both an immune system response as well as in vivo metabolism of the biologic drug, respectively. Interpreting, assessing, and predicting immunogenicity is therefore critical in the development of a biotherapeutic.
Predicting and assessing immunogenicity early in drug discovery ensure the likelihood of success as the biologic drug candidate progresses through the discovery and development pipeline. Pharma and Biopharma companies may have their own proprietary methods for immunogenicity and PK/PD assessment as part of their developability scoring.
PerkinElmer offers a complete solution of tools to help developability scoring, which represents our informatics solution to help predict known sequence activity relationships, to in vivo biodistribution studies and through a variety of immunoassay platforms.
